Skip to main content

GeneScan Takes 25.1 Percent Stake in MWG, MWG Sells Convertible Bond for 6.5M Euros

NEW YORK, Jan. 3 (GenomeWeb News) - GeneScan Europe has acquired 25.1 percent of MWG Biotech pursuant to a stock-purchase agreement with two major shareholders announced last month.

 

Specific details of the sale, which included 8,656,500 shares of MWG, were not disclosed.

 

GeneScan also has purchased about €2 million in MWG convertible bonds from the shareholders.

 

MWG Biotech said separately that it has sold convertible bonds totaling €6.5 million. Proceeds of the sale will be used to support MWG's ongoing restructuring, the company noted.

 

In November, the company said it expected to raise €10 million through the sale of its convertible bonds.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.